news
Short article material
Acquisition would broaden Hologic’s oncology diagnostics portfolio to assist notify treatment choices for more females with breast cancer
news Check in or Create an Account
or
Short article material
MARLBOROUGH, Mass.– Hologic, an international leader in females’s health, today revealed that it has actually signed a conclusive contract to get Reveal Genomics, an accuracy oncology business based in Barcelona, Spain, that establishes innovative genomic diagnostic tests to assist customized cancer treatment, including its HER2DX test to assist enhance treatment for clients with HER2-positive breast cancer.
Post material
Post material
Short article material
Breast cancer stays among the most considerable health obstacles ladies deal with today. Expose Genomics’ tests are extremely complementary to Hologic’s existing oncology diagnostics, consisting of the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to assist notify choices relating to prolonged endocrine treatment in females with HR+ early-stage breast cancer.
Post material
By registering you grant get the above newsletter from Postmedia Network Inc.
Post material
The mix of Hologic’s existing screening with Reveal Genomics’ portfolio represents a substantial growth of Hologic’s diagnostic oncology services, with the combined offering of brand-new and current screening anticipated to assist notify treatment choices for more females with breast cancer.
Short article material
“Reveal Genomics’ portfolio is a strong tactical enhance to our existing oncology offering within Diagnostic Solutions and would permit us to support much more ladies identified with breast cancer,” stated Vitor Rocha, CEO, Diagnostic Solutions at Hologic. “This acquisition shows our dedication to development and meaningfully broadens our capability to notify breast cancer treatment choices, straight advancing our function to allow much healthier lives all over, every day.”
Post material
“We established Reveal Genomics to bring accuracy oncology closer to clients and enhance breast cancer treatment choices,” stated Patricia Villagrasa-Gonzalez, CEO and co-founder of Reveal Genomics. “Joining Hologic offers us the scale and abilities to speed up that objective and reach a lot more clients worldwide.”
Short article material
Conclusion of the acquisition goes through Spanish regulative approval and other popular closing conditions.
Post material
About Hologic, Inc.
Short article material
Hologic, Inc. is an international leader in ladies’s health devoted to establishing ingenious medical innovations that efficiently spot, detect and deal with health conditions and raise the requirement of care all over the world. For more information, see www.hologic.com and get in touch with us on LinkedIn, Facebook, X, Instagram and YouTube.
Short article material
About Reveal Genomics
Short article material
EXPOSE GENOMICS, S.L. is a biotechnology start-up looking for to alter the method biomarkers are utilized in oncology. It is concentrated on establishing ingenious diagnostic tools to specify the very best restorative alternatives for clients with cancer. The business utilizes pioneering strategies, advanced computer system applications, and artificial intelligence to expose brand-new cancer research study information.
Short article material
Positive Statements
Post material
Short article material
This press release might consist of positive info that includes threats and unpredictabilities, consisting of declarations about the proposed acquisition of the oncology services company of Reveal Genomics and the expected advantages, timing and results of the deal, along with declarations about making use of Hologic and Reveal Genomics items. There can be no guarantee the deal will be finished on the expected terms or timing, or at all, consisting of since needed regulative approvals or other traditional closing conditions are not pleased. There can likewise be no guarantee that Hologic will effectively incorporate Reveal Genomics’ company and workers, that the gotten items will attain the advantages explained herein, that such advantages will be reproduced in any specific way with regard to a specific client, or that these items will be commercially effective or attain any anticipated level of sales, consisting of as an outcome of protection and compensation choices by third-party payers. Hologic specifically disclaims any commitment or carrying out to launch openly any updates or modifications to any such declarations provided herein to show any modification in expectations or any modification in occasions, conditions or scenarios on which any such declarations are based.
Short article material
Short article material
Post material
Post material
View source variation on businesswire.com:
Short article material
Short article material
Short article material
Contacts
Short article material
Media Contact
Short article material
Post material
Bridget Perry
Short article material
Short article material
Senior Citizen Director, Corporate Communications
Post material
Short article material
(+1) 508.263.8654
Post material
Short article material
Post material
Discover more from PMN S.P.O.R.T.S - A PRIME MEDIA NETWORK BRAND
Subscribe to get the latest posts sent to your email.
